Pfizer licenses Starna in vivo CAR-T programs in $2.6bn deal
Pfizer will pay $330 million upfront and up to $2.3 billion in milestones, plus royalties, for global rights outside Greater China to three preclinical autoimmune programs.
. 2-minute read.

Pfizer has signed an exclusive licensing agreement with Starna Therapeutics covering three preclinical in vivo CAR-T programs for autoimmune diseases, Drug Discovery News reported. MedCity News described Starna’s platform as RNA-based medicines delivered by lipid nanoparticles, with technology that engineers the particles to reach targets beyond the liver and reprogram a patient’s cells into a cell therapy inside the body.
Pfizer will pay Starna $330 million up front and up to $2.3 billion in development and commercial milestones, plus royalties on sales of any approved products, according to BioPharma Dive. The agreement gives Pfizer rights outside Greater China, options to license other projects, and an option to expand the territory to include Greater China. MedCity News reported that the specific targets and indications covered by the deal were not disclosed. BioPharma Dive said the deal is Pfizer’s first move into in vivo CAR-T.
BioPharma Dive said Pfizer emphasized its RNA experience after the Covid-19 vaccine Comirnaty, which it developed with BioNTech, and plans to manufacture the therapies for clinical trials at its U.S. facilities. MedCity News added that Pfizer will lead clinical development outside Greater China and hold exclusive commercialization rights there if any products reach approval.
Marketed CAR-T cell therapies for cancer, such as Johnson & Johnson’s Carvykti, use an ex vivo process in which a patient’s cells are harvested, modified and reinfused, BioPharma Dive noted. Developers hope in vivo approaches can eliminate much of that manufacturing and preparation work and avoid the chemotherapy conditioning that typically accompanies ex vivo therapy. The Starna programs have not yet entered clinical trials, which means no safety or efficacy data are available from them.
“In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short,” Michael Vincent, Pfizer’s chief inflammation and immunology officer, said in a statement reported by MedCity News. “Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches.”
However, in vivo cell therapy remains early-stage and competitive. BioPharma Dive reported that AstraZeneca, AbbVie, Gilead Sciences and Bristol Myers Squibb have made acquisitions in the area in the past two years, while Eli Lilly announced two buyouts in 2026. Novartis and Bristol Myers Squibb have recently paused trials of CAR-T therapies in autoimmune conditions over safety concerns, according to BioPharma Dive. The Starna agreement is at least Pfizer’s fifth major alliance with a Chinese company since the start of 2025, BioPharma Dive added.
Sources: Drug Discovery News Magazine, BioPharma Dive, MedCity News
Corrections. Report an error to corrections@clinicalobserver.com. Read our corrections policy.